Fig. 2

A Copy number variation (CNV) levels (expressed here as a percentage of the total genome) demonstrating a significant difference between overall CNV in all grades of IDH-mutant astrocytoma (p < 0.0001), between IDH-wildtype tumors histologically consistent with grade 2 and their histologic grade 3 and 4 counterparts (p < 0.0001), and between grade 2 and 3 oligodendroglioma (p = 0.0036), B copy number burden plot demonstrating a significant increase in the mean CNV in IDH-mutant astrocytoma (mean increase of 7.9 ± 1.1% in initial biopsy/resection versus recurrence; n = 22; p = 0.0012), and trend toward increased mean CNV percentage in IDH-wildtype glioblastoma (mean increase of 6.4 ± 1.1% in initial biopsy/resection versus recurrence; n = 13; p = 0.0795), C copy number burden plot demonstrating an inverse relationship between CNV in initial diffuse glioma biopsy and overall patient survival (r = -0.2507, p < 0.0001), and receiver operating characteristic (ROC) curves demonstrating the relative value of CNV in predicting outcome in D IDH-mutant astrocytoma (Area Under Curve (AUC) = 0.77; p < 0.0001), E IDH-wildtype glioblastoma (AUC = 0.62; p = 0.0135), and F oligodendroglioma (AUC = 0.54; p = 0.3943). All data are derived from Richardson et al. 2021 [97] and Liu et al. 2022 [62]